Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDO2 | P48775 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 6-Fluoro-3-Phenylindole SCHEMBL3626834 | 0.79 | TDO2 (0.68) | TDO2 | |
| SCHEMBL16990272 | 0.71 | TDO2 (1.00) | TDO2 | |
| SCHEMBL16990332 | 0.71 | TDO2 (0.59) | TDO2 | |
| SCHEMBL18509572 | 0.70 | TDO2 (1.00) | TDO2 | |
| SCHEMBL18498729 | 0.70 | TDO2 (1.00) | TDO2 | |
| SCHEMBL18509909 | 0.70 | TDO2 (0.75) | TDO2 | |
| SCHEMBL18510010 | 0.70 | TDO2 (0.77) | TDO2 | |
| SCHEMBL18510011 | 0.70 | TDO2 (0.55) | TDO2 | |
| SCHEMBL18498736 | 0.70 | TDO2 (1.00) | TDO2 | |
| SCHEMBL20451462 | 0.70 | TDO2 (0.60) | TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3105225-A1 | NOVEL 3-(INDOL-3-YL)-PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | iTeos Therapeutics (BE) | 2016-12-21 | — | — | EP | claimed |
| WO-2015121812-A1 | NOVEL 3-(INDOL-3-YL)-PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | ITEOS THERAPEUTICS (BE) | 2015-08-20 | — | — | WO | claimed |
| US-20150225367-A1 | NOVEL 3-(INDOL-3-YL)-PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | ITEOS THERAPEUTICS (BE) | 2015-08-13 | — | — | US | claimed |
| US-9758505-B2 | 3-(indol-3-yl)-pyridine derivatives, pharmaceutical compositions and methods for use | ITEOS THERAPEUTICS (BE) | 2017-09-12 | — | — | US | disclosed |
| US-9758505-B2 | 3-(indol-3-yl)-pyridine derivatives, pharmaceutical compositions and methods for use | ITEOS THERAPEUTICS (BE) | 2017-09-12 | — | — | US | disclosed |
| WO-2015121812-A1 | NOVEL 3-(INDOL-3-YL)-PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | ITEOS THERAPEUTICS (BE) | 2015-08-20 | — | — | WO | disclosed |
| US-20150225367-A1 | NOVEL 3-(INDOL-3-YL)-PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | ITEOS THERAPEUTICS (BE) | 2015-08-13 | — | — | US | disclosed |
| US-20150225367-A1 | NOVEL 3-(INDOL-3-YL)-PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | ITEOS THERAPEUTICS (BE) | 2015-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225367-A1 | NOVEL 3-(INDOL-3-YL)-PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | TDO2, IDO1, IDO2 | TDO2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.